{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-1587"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-1587","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Omega-3 Fatty Acids as Therapeutic Options for the Treatment of B-cell Chronic Lymphocytic Leukemia","abstract":"B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the western world. CLL is often diagnosed in the asymptomatic (early-stage) stages. However, approximately 50% of these patients will progress to advanced, symptomatic disease and require therapy. Current treatment options are limited due to progressive drug resistance and severe drug-induced toxicities which are often too toxic for the elderly or those with co-morbidities. Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic CLL to symptomatic CLL or enhance the effects of actively used chemo-therapeutic drugs in patients who require therapy would be clinically beneficial. In our studies, we evaluated the use of omega-3 (n-3) fatty acids as therapeutic options for CLL utilizing both a clinical supplementation model (FWA #00002704) as well as a cell culture model. The primary objective of the initial study was to determine whether consumption of n-3 could suppress activation of nuclear factor kappa B (NF B) in lymphocytes from patients diagnosed with early stage CLL. The primary objective of the follow-up study was to evaluate whether n-3 eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) could enhance the chemo-sensitivity of CLL-derived cell lines EHEB and MEC-2 and pro-lymphocytic leukemiaderived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine or fludarabine in vitro. ur initial study indicated that consumption of an EPA + DHA containing n-3 supplement 1) suppressed activation of NF B in lymphocytes from patients diagnosed with early stage CLL, 2) increased molar concentrations of n-3 in the plasma, 3) increased the chemosensitivity of lymphocytes to doxorubicin in an in vitro assay and 4) decreased the expression of 32 genes in lymphocytes. Targeting the NF B pathway is proposed as a therapy for CLL. Suppression of NF B activation by n-3 may slow the progression of the disease to symptomatic disease where therapy is required. However, a definitive clinical trial will be needed to determine if n-3 can slow the progression of CLL. The aim of the second study was to expanding upon the chemo-sensitization capabilities of n-3. In these trials, cell-cycle analyses, Annexin-V assays, assays for malondialdehyde (a measure of lipid peroxidation) and DCF fluorescence assays (a measure of reactive oxygen species (ROS) generation) were performed to explore potential mechanism(s) through which enhanced chemo-sensitivity was achieved. Results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and with drug treatment increased cell death and induced G2/M arrest in a cell-type specific manner; 3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA. N-3 are a promising therapeutic intervention for the treatment of CLL with the capacity to potentially slow the progression of the disease and enhance the chemo-sensitivity of malignant cells to chemo-therapeutic drugs and warrants further investigation. Slowing the progression of the disease would be clinically beneficial. Enhanced chemo-sensitivity would be expected to increase drug efficacy and potential reductions in drug dosage and drug-induced toxicities.","abstract_html":"B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the western world. CLL is often diagnosed in the asymptomatic (early-stage) stages. However, approximately 50% of these patients will progress to advanced, symptomatic disease and require therapy. Current treatment options are limited due to progressive drug resistance and severe drug-induced toxicities which are often too toxic for the elderly or those with co-morbidities. Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic CLL to symptomatic CLL or enhance the effects of actively used chemo-therapeutic drugs in patients who require therapy would be clinically beneficial. In our studies, we evaluated the use of omega-3 (n-3) fatty acids as therapeutic options for CLL utilizing both a clinical supplementation model (FWA #00002704) as well as a cell culture model. The primary objective of the initial study was to determine whether consumption of n-3 could suppress activation of nuclear factor kappa B (NF B) in lymphocytes from patients diagnosed with early stage CLL. The primary objective of the follow-up study was to evaluate whether n-3 eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) could enhance the chemo-sensitivity of CLL-derived cell lines EHEB and MEC-2 and pro-lymphocytic leukemiaderived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine or fludarabine in vitro. ur initial study indicated that consumption of an EPA + DHA containing n-3 supplement 1) suppressed activation of NF B in lymphocytes from patients diagnosed with early stage CLL, 2) increased molar concentrations of n-3 in the plasma, 3) increased the chemosensitivity of lymphocytes to doxorubicin in an in vitro assay and 4) decreased the expression of 32 genes in lymphocytes. Targeting the NF B pathway is proposed as a therapy for CLL. Suppression of NF B activation by n-3 may slow the progression of the disease to symptomatic disease where therapy is required. However, a definitive clinical trial will be needed to determine if n-3 can slow the progression of CLL. The aim of the second study was to expanding upon the chemo-sensitization capabilities of n-3. In these trials, cell-cycle analyses, Annexin-V assays, assays for malondialdehyde (a measure of lipid peroxidation) and DCF fluorescence assays (a measure of reactive oxygen species (ROS) generation) were performed to explore potential mechanism(s) through which enhanced chemo-sensitivity was achieved. Results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and with drug treatment increased cell death and induced G2/M arrest in a cell-type specific manner; 3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA. N-3 are a promising therapeutic intervention for the treatment of CLL with the capacity to potentially slow the progression of the disease and enhance the chemo-sensitivity of malignant cells to chemo-therapeutic drugs and warrants further investigation. Slowing the progression of the disease would be clinically beneficial. Enhanced chemo-sensitivity would be expected to increase drug efficacy and potential reductions in drug dosage and drug-induced toxicities.","abstract_has_math":false,"creators":["Fahrmann, Johannes Francois"],"institution":null,"degree_name":"Biomedical Sciences","degree_level":"Dissertation","degree_discipline":"Joan C. Edwards School of Medicine","degree_department":null,"school":null,"contributors":["W. Elaine Hardman","Monica Valentovic","Pier Paolo Claudio"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:56:20Z","subjects":["Biochemistry","Biochemistry, Biophysics, and Structural Biology","Cancer Biology","Cell and Developmental Biology","Cell Biology","Life Sciences","B-Cell Chronic Lymphocytic Leukemia","Chemo-sensitivity","Nuclear Factor Kappa B","Omega-3 Fatty Acids"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/586","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/586","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-1587","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["W. Elaine Hardman","Monica Valentovic","Pier Paolo Claudio"]},{"key":"dc:creator","label":"Author","values":["Fahrmann, Johannes Francois"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2013-08-08T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Joan C. Edwards School of Medicine"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Biomedical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biochemistry","Biochemistry, Biophysics, and Structural Biology","Cancer Biology","Cell and Developmental Biology","Cell Biology","Life Sciences","B-Cell Chronic Lymphocytic Leukemia","Chemo-sensitivity","Nuclear Factor Kappa B","Omega-3 Fatty Acids"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/586"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the western world. CLL is often diagnosed in the asymptomatic (early-stage) stages. However, approximately 50% of these patients will progress to advanced, symptomatic disease and require therapy. Current treatment options are limited due to progressive drug resistance and severe drug-induced toxicities which are often too toxic for the elderly or those with co-morbidities. Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic CLL to symptomatic CLL or enhance the effects of actively used chemo-therapeutic drugs in patients who require therapy would be clinically beneficial. In our studies, we evaluated the use of omega-3 (n-3) fatty acids as therapeutic options for CLL utilizing both a clinical supplementation model (FWA #00002704) as well as a cell culture model. The primary objective of the initial study was to determine whether consumption of n-3 could suppress activation of nuclear factor kappa B (NF B) in lymphocytes from patients diagnosed with early stage CLL. The primary objective of the follow-up study was to evaluate whether n-3 eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) could enhance the chemo-sensitivity of CLL-derived cell lines EHEB and MEC-2 and pro-lymphocytic leukemiaderived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine or fludarabine in vitro. ur initial study indicated that consumption of an EPA + DHA containing n-3 supplement 1) suppressed activation of NF B in lymphocytes from patients diagnosed with early stage CLL, 2) increased molar concentrations of n-3 in the plasma, 3) increased the chemosensitivity of lymphocytes to doxorubicin in an in vitro assay and 4) decreased the expression of 32 genes in lymphocytes. Targeting the NF B pathway is proposed as a therapy for CLL. Suppression of NF B activation by n-3 may slow the progression of the disease to symptomatic disease where therapy is required. However, a definitive clinical trial will be needed to determine if n-3 can slow the progression of CLL. The aim of the second study was to expanding upon the chemo-sensitization capabilities of n-3. In these trials, cell-cycle analyses, Annexin-V assays, assays for malondialdehyde (a measure of lipid peroxidation) and DCF fluorescence assays (a measure of reactive oxygen species (ROS) generation) were performed to explore potential mechanism(s) through which enhanced chemo-sensitivity was achieved. Results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and with drug treatment increased cell death and induced G2/M arrest in a cell-type specific manner; 3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA. N-3 are a promising therapeutic intervention for the treatment of CLL with the capacity to potentially slow the progression of the disease and enhance the chemo-sensitivity of malignant cells to chemo-therapeutic drugs and warrants further investigation. Slowing the progression of the disease would be clinically beneficial. Enhanced chemo-sensitivity would be expected to increase drug efficacy and potential reductions in drug dosage and drug-induced toxicities."]},{"key":"dc:title","label":"Title","values":["Omega-3 Fatty Acids as Therapeutic Options for the Treatment of B-cell Chronic Lymphocytic Leukemia"]}]}],"canonical_facts":{"dc:contributor":["W. Elaine Hardman","Monica Valentovic","Pier Paolo Claudio"],"dc:creator":["Fahrmann, Johannes Francois"],"dc:date.available":["2013-08-08T07:00:00Z"],"dc:date.created":["2013-01-01T08:00:00Z"],"dc:description.abstract":["B-cell chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the western world. CLL is often diagnosed in the asymptomatic (early-stage) stages. However, approximately 50% of these patients will progress to advanced, symptomatic disease and require therapy. Current treatment options are limited due to progressive drug resistance and severe drug-induced toxicities which are often too toxic for the elderly or those with co-morbidities. Therefore, a non-toxic therapeutic intervention that could slow the progression of asymptomatic CLL to symptomatic CLL or enhance the effects of actively used chemo-therapeutic drugs in patients who require therapy would be clinically beneficial. In our studies, we evaluated the use of omega-3 (n-3) fatty acids as therapeutic options for CLL utilizing both a clinical supplementation model (FWA #00002704) as well as a cell culture model. The primary objective of the initial study was to determine whether consumption of n-3 could suppress activation of nuclear factor kappa B (NF B) in lymphocytes from patients diagnosed with early stage CLL. The primary objective of the follow-up study was to evaluate whether n-3 eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) could enhance the chemo-sensitivity of CLL-derived cell lines EHEB and MEC-2 and pro-lymphocytic leukemiaderived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine or fludarabine in vitro. ur initial study indicated that consumption of an EPA + DHA containing n-3 supplement 1) suppressed activation of NF B in lymphocytes from patients diagnosed with early stage CLL, 2) increased molar concentrations of n-3 in the plasma, 3) increased the chemosensitivity of lymphocytes to doxorubicin in an in vitro assay and 4) decreased the expression of 32 genes in lymphocytes. Targeting the NF B pathway is proposed as a therapy for CLL. Suppression of NF B activation by n-3 may slow the progression of the disease to symptomatic disease where therapy is required. However, a definitive clinical trial will be needed to determine if n-3 can slow the progression of CLL. The aim of the second study was to expanding upon the chemo-sensitization capabilities of n-3. In these trials, cell-cycle analyses, Annexin-V assays, assays for malondialdehyde (a measure of lipid peroxidation) and DCF fluorescence assays (a measure of reactive oxygen species (ROS) generation) were performed to explore potential mechanism(s) through which enhanced chemo-sensitivity was achieved. Results indicated that: 1) EPA and DHA differentially sensitized B-leukemic cell lines EHEB, JVM-2 and MEC-2 to doxorubicin, vincristine and fludarabine in vitro; 2) n-3 alone and with drug treatment increased cell death and induced G2/M arrest in a cell-type specific manner; 3) lipid peroxidation increased in the presence of n-3; 4) there was higher lipid peroxidation in MEC-2 cells in presence of DHA and doxorubicin than with either alone; 5) n-3 increased generation of ROS in MEC-2, and 6) the addition of vitamin-E abrogated the increase in ROS generation and chemo-sensitivity of MEC-2 to doxorubicin by DHA. N-3 are a promising therapeutic intervention for the treatment of CLL with the capacity to potentially slow the progression of the disease and enhance the chemo-sensitivity of malignant cells to chemo-therapeutic drugs and warrants further investigation. Slowing the progression of the disease would be clinically beneficial. Enhanced chemo-sensitivity would be expected to increase drug efficacy and potential reductions in drug dosage and drug-induced toxicities."],"dc:identifier":["https://mds.marshall.edu/etd/586"],"dc:subject":["Biochemistry","Biochemistry, Biophysics, and Structural Biology","Cancer Biology","Cell and Developmental Biology","Cell Biology","Life Sciences","B-Cell Chronic Lymphocytic Leukemia","Chemo-sensitivity","Nuclear Factor Kappa B","Omega-3 Fatty Acids"],"dc:title":["Omega-3 Fatty Acids as Therapeutic Options for the Treatment of B-cell Chronic Lymphocytic Leukemia"],"thesis:degree_discipline":["Joan C. Edwards School of Medicine"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Biomedical Sciences"]},"updated_at":"2026-11-21T19:56:20Z"}